Browsing Tag
Cardiovascular
2 posts
Milvexian setback: Phase 3 Librexia ACS trial discontinued as interim data shows futility for Bristol Myers Squibb and Johnson & Johnson
Find out how the Librexia ACS trial discontinuation reshapes the future of milvexian and what it means for cardiovascular drug development today.
November 14, 2025
Can Merck rebuild its cardiovascular empire post-Keytruda? A closer look at its next decade of drug growth
With Keytruda’s patent expiry nearing, Merck is betting on enlicitide and sotatercept to build a new cardiovascular empire. Can it succeed?
June 10, 2025